Impaired memory and executive function associated with decreased medial temporal and prefrontal blood flow in Clinical Dementia Rating 0.5 status: The Osaki-Tajiri project

Psychogeriatrics

Volumn 12, Issue 1, 2012, Pages 27-33

  Inoue, Kentaro ^a   Meguro, Kenichi ^b,c   Akanuma, Kyoko ^b,c   Meguro, Mitsue ^b,c   Yamaguchi, Satoshi ^b,c   Fukuda, Hiroshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Osaki Tajiri SKIP Center   (Japan)

Author keywords

CASI; CBF; CDR 0.5; SPECT

Indexed keywords

IOFETAMINE I 123;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MEDIAL TEMPORAL BLOOD FLOW; MEMORY DISORDER; PREFRONTAL BLOOD FLOW; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; TEMPORAL LOBE; VOXEL BASED MORPHOMETRY;

AGED; AGED, 80 AND OVER; BRAIN MAPPING; COHORT STUDIES; DEMENTIA; EXECUTIVE FUNCTION; FEMALE; HUMANS; JAPAN; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84858379384     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2011.00384.x     Document Type: Article

References (38)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
2. Winblad B, Palmer K, Kivipelto M etal. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med 2004; 256: 240-246.
3. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
4. Meguro K, Ishii H, Yamaguchi S etal. Prevalence and cognitive performances of clinical dementia rating 0.5 and mild cognitive impairment in Japan. The Tajiri project. Alzheimer Dis Assoc Disord 2004; 18: 3-10.
5. Meguro K, Ishii H, Kasuya M etal. Incidence of dementia and associated risk factors in Japan: the Osaki-Tajiri project. J Neurol Sci 2007; 260: 175-182.
6. Teng EL, Hasegawa K, Homma A etal. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994; 6: 45-58. discussion 62.
7. Nakata E, Kasai M, Kasuya M etal. Combined memory and executive function tests can screen mild cognitive impairment and converters to dementia in a community: the Osaki-Tajiri project. Neuroepidemiology 2009; 33: 103-110.
8. Morris JC, McKeel DW, Jr, Storandt M etal. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991; 41: 469-478.
9. Morris JC, Storandt M, Miller JP etal. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-944.
11. Borroni B, Anchisi D, Paghera B etal. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 2006; 27: 24-31.
12. Nobili F, De Carli F, Frisoni GB etal. SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. J Alzheimers Dis 2009; 17: 761-772.
13. Nobili F, Frisoni GB, Portet F etal. Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study. J Neurol 2008; 255: 1344-1353.
14. Huang C, Wahlund LO, Almkvist O etal. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 2003; 19: 1137-1144.
15. Johnson KA, Moran EK, Becker JA, Blacker D, Fischman AJ, Albert MS. Single photon emission computed tomography perfusion differences in mild cognitive impairment. J Neurol Neurosurg Psychiatry 2007; 78: 240-247.
16. Encinas M, De Juan R, Marcos A etal. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease. Eur J Nucl Med Mol Imaging 2003; 30: 1473-1480.
17. Ishiwata A, Sakayori O, Minoshima S, Mizumura S, Kitamura S, Katayama Y. Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study. Acta Neurol Scand 2006; 114: 91-96.
18. Hirao K, Ohnishi T, Hirata Y etal. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005; 28: 1014-1021.
19. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
20. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink T, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York: The Haworth Press, 1986; 165-173.
21. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922-935.
22. Zhang MY, Katzman R, Salmon D etal. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27: 428-437.
23. McKeith IG, Galasko D, Kosaka K etal. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
24. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416-418.
25. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25: 638-643.
26. Takeuchi R, Yonekura Y, Matsuda H, Konishi J. Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET. Eur J Nucl Med Mol Imaging 2002; 29: 331-341.
27. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19: 1233-1239.
28. Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science 1991; 253: 1380-1386.
29. Yamaguchi S, Meguro K, Ishii H, Meguro M, Akanuma K. Assessment of mental deterioration with the Cognitive Abilities Screening Instrument (CASI) and glucose hypometabolism in Alzheimer's disease: the Osaki-Tajiri project. J Clin Neurosci 2009; 16: 1430-1434.
30. Nishi H, Sawamoto N, Namiki C etal. Correlation between cognitive deficits and glucose hypometabolism in mild cognitive impairment. J Neuroimaging 2010; 20: 29-36.
31. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32: 486-510.
32. Huang C, Eidelberg D, Habeck C etal. Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT. Neurobiol Aging 2007; 28: 1062-1069.
33. Hashimoto R, Meguro K, Yamaguchi S etal. Executive dysfunction can explain word-list learning disability in very mild Alzheimer's disease: the Tajiri project. Psychiatry Clin Neurosci 2004; 58: 54-60.
34. Kume K, Hanyu H, Murakami M etal. Frontal Assessment Battery and brain perfusion images in amnestic mild cognitive impairment. Geriatr Gerontol Int 2011; 11: 77-82.
35. Bracco L, Bessi V, Piccini C, Mosconi L, Pupi A, Sorbi S. Metabolic correlates of executive dysfunction. Different patterns in mild and very mild Alzheimer's disease. J Neurol 2007; 254: 1052-1065.
36. Inoue K, Ito H, Goto R etal. Apparent CBF decrease with normal aging due to partial volume effects: MR-based partial volume correction on CBF SPECT. Ann Nucl Med 2005; 19: 283-290.
37. Ibanez V, Pietrini P, Alexander GE etal. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998; 50: 1585-1593.
38. Matsuda H, Kanetaka H, Ohnishi T etal. Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002; 29: 1502-1505.